Advocacy

As Congress considers whether to codify Most Favored Nation (MFN) drug pricing into statute, recent comments by CMS Administrator Dr. Mehmet Oz...

The U.S. Food and Drug Administration (FDA) has announced a significant shift in its drug approval standards, moving away from the long-standing...

MichBio is proud to voice strong support for HB 5031, legislation that would renew the Tax Increment Financing (TIF) authority underpinning...

MichBio has expressed strong support for SB 704, legislation that would establish a State Reference Laboratory to strengthen oversight,...

The January 30, 2026 announcement of a Unified NIH Funding Strategy marks one of the most consequential shifts in federal biomedical research...

National Institutes of Health (NIH) Director Dr. Jayanta “Jay” Bhattacharya faced a pointed round of bipartisan scrutiny at a Senate...

Michigan House Bill 4878 cleared the House Health Policy Committee this week, advancing with a committee substitute (H-3) and moving next to...

In overlapping victories for biotech innovation and public health, the U.S. Senate and House of Representatives have approved two landmark pieces...

Friends — Michigan has world-class science, a proud manufacturing legacy and thousands of bioscience jobs. But the cold truth is this:...

A sweeping government funding package now before the U.S. Senate carries major implications for the life sciences sector - touching drug...

The recent White House announcement of “The Great Healthcare Plan” landed with familiar fanfare: bold promises to lower drug prices,...

A coalition of life sciences investors, Incubate, says capital is beginning to flow back into rare disease drug development, citing more than $1...